CMPS vs. HROW, PAHC, ABCL, COGT, PHVS, NTLA, CVAC, AUPH, WVE, and CALT
Should you be buying COMPASS Pathways stock or one of its competitors? The main competitors of COMPASS Pathways include Harrow (HROW), Phibro Animal Health (PAHC), AbCellera Biologics (ABCL), Cogent Biosciences (COGT), Pharvaris (PHVS), Intellia Therapeutics (NTLA), CureVac (CVAC), Aurinia Pharmaceuticals (AUPH), WAVE Life Sciences (WVE), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry.
COMPASS Pathways vs. Its Competitors
COMPASS Pathways (NASDAQ:CMPS) and Harrow (NASDAQ:HROW) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.
46.2% of COMPASS Pathways shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 3.9% of COMPASS Pathways shares are owned by insiders. Comparatively, 13.7% of Harrow shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Harrow has higher revenue and earnings than COMPASS Pathways. Harrow is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks.
COMPASS Pathways currently has a consensus price target of $17.00, suggesting a potential upside of 358.22%. Harrow has a consensus price target of $63.83, suggesting a potential upside of 79.21%. Given COMPASS Pathways' higher possible upside, equities analysts clearly believe COMPASS Pathways is more favorable than Harrow.
COMPASS Pathways has a net margin of 0.00% compared to Harrow's net margin of -10.19%. Harrow's return on equity of -25.01% beat COMPASS Pathways' return on equity.
COMPASS Pathways has a beta of 2.12, indicating that its share price is 112% more volatile than the S&P 500. Comparatively, Harrow has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500.
In the previous week, Harrow had 8 more articles in the media than COMPASS Pathways. MarketBeat recorded 13 mentions for Harrow and 5 mentions for COMPASS Pathways. COMPASS Pathways' average media sentiment score of 0.70 beat Harrow's score of 0.64 indicating that COMPASS Pathways is being referred to more favorably in the media.
Summary
Harrow beats COMPASS Pathways on 10 of the 15 factors compared between the two stocks.
Get COMPASS Pathways News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMPS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CMPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
COMPASS Pathways Competitors List
Related Companies and Tools
This page (NASDAQ:CMPS) was last updated on 7/15/2025 by MarketBeat.com Staff
Free CMPS Stock Alerts